ADMET considerations for phosphodiesterase-5 inhibitors.
about
Preclinical pharmacokinetics of TPN729MA, a novel PDE5 inhibitor, and prediction of its human pharmacokinetics using a PBPK model.New methods for the discovery and synthesis of PDE7 inhibitors as new drugs for neurological and inflammatory disorders.Pharmacokinetic evaluation of sildenafil as a pulmonary hypertension treatment.
P2860
ADMET considerations for phosphodiesterase-5 inhibitors.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
ADMET considerations for phosphodiesterase-5 inhibitors.
@en
type
label
ADMET considerations for phosphodiesterase-5 inhibitors.
@en
prefLabel
ADMET considerations for phosphodiesterase-5 inhibitors.
@en
P2860
P50
P1476
ADMET considerations for phosphodiesterase-5 inhibitors.
@en
P2860
P304
P356
10.1517/17425255.2012.698610
P407
P577
2012-07-07T00:00:00Z